Compare Eli Lilly And Co (LLY) vs UnitedHealth Group Inc (UNH) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

UnitedHealth Group (UNH) trades at $421.55, down 1.07% today, with strong bullish technical signals and consistent earnings beats. Revenue reached $447.57B in 2025, though net margins compressed to 2.68%. The company maintains robust cash flow from operations at $19.70B and announced a $2.32 dividend for H1 2026. Recent news highlights strategic moves to reduce pediatric prior authorizations, aiming to improve care access and operational efficiency.

Outlook remains positive with analyst consensus targeting $466.41, representing ~11% upside. Key opportunities include aging demographics and tech-driven healthcare adoption. Risks involve regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. Institutional sentiment is strongly bullish with 82.7% buy ratings, supporting long-term growth prospects amid sector tailwinds.